Sallevelt, Bastiaan T. G. M. http://orcid.org/0000-0003-4687-4048
Huibers, Corlina J. A.
Heij, Jody M. J. Op
Egberts, Toine C. G.
van Puijenbroek, Eugène P.
Shen, Zhengru
Spruit, Marco R.
Jungo, Katharina Tabea
Rodondi, Nicolas
Dalleur, Olivia
Spinewine, Anne
Jennings, Emma
O’Mahony, Denis
Wilting, Ingeborg
Knol, Wilma
Clinical trials referenced in this document:
Documents that mention this clinical trial
Benzodiazepine Receptor Agonists Use and Cessation Among Multimorbid Older Adults with Polypharmacy: Secondary Analysis from the OPERAM Trial
https://doi.org/10.1007/s40266-023-01029-1
Frequency and Acceptance of Clinical Decision Support System-Generated STOPP/START Signals for Hospitalised Older Patients with Polypharmacy and Multimorbidity
https://doi.org/10.1007/s40266-021-00904-z
Hospital physicians’ and older patients’ agreement with individualised STOPP/START-based medication optimisation recommendations in a clinical trial setting
https://doi.org/10.1007/s41999-022-00633-5
Rationale and design of OPtimising thERapy to prevent Avoidable hospital
admissions in Multimorbid older people (OPERAM): a cluster randomised
controlled trial
https://doi.org/10.1136/bmjopen-2018-026769
Optimizing Therapy to Prevent Avoidable Hospital Admissions in Multimorbid Older Adults (OPERAM): cluster randomised controlled trial
https://doi.org/10.1136/bmj.n1585
Funding for this research was provided by:
horizon 2020 (634238, 634238, 634238, 634238, 634238, 634238, 634238, 634238, 634238, 634238)
schweizerischer nationalfonds zur förderung der wissenschaftlichen forschung (NFP74 407440_167465)
staatssekretariat für bildung, forschung und innovation (15.0137)
Article History
Accepted: 3 November 2021
First Online: 8 December 2021
Declarations
:
: This work is part of the OPERAM project supported by the EU’s Horizon 2020 research and innovation programme under grant agreement no. 634238 and by the Swiss State Secretariat for Education, Research and Innovation under contract number 15.0137. The work of Katharina Tabea Jungo was supported by the Swiss National Science Foundation, grant no. NFP74 407440_167465. The opinions expressed herein are those of the authors and do not necessarily reflect the official views of the European Commission or the Swiss government. The funder of the study had no role in the study design; data collection, analysis, and interpretation; or writing of the report.
: Denis O’Mahony has a patent ‘A Prescription Decision Support System (based on screening tool of older person’s prescriptions and screening tool to alert to the right treatment [STOPP/START] prescribing rules)’ issued to the European Patent Office (Munich). Marco R Spruit received a 2011 grant and personal fees from Spru IT before the conduct of the study and reports a settlement agreement between Spru IT and Utrecht University, in which all STRIP assistant intellectual property is transferred to Utrecht University in exchange for obtaining a free but non-exclusive right to provide STRIP assistant consultancy or support services, or both, on a commercial basis and to update the STRIP assistant until June 2023. Bastiaan TGM Sallevelt, Corlina JA Huibers, Jody MJ Op Heij, Toine CG Egberts, Eugène P van Puijenbroek, Zhengru Shen, Katharina Tabea Jungo, Nicolas Rodondi, Olivia Dalleur, Anne Spinewine, Emma Jennings, Ingeborg Wilting, and Wilma Knol have no conflicts of interest that are directly relevant to the content of this article.
: Data for this study will be made available to others in the scientific community upon request after publication. Data will be made available for scientific purposes for researchers whose proposed use of the data has been approved by a publication committee.
: The OPERAM trial was approved by the independent research ethics committees at each participating site (lead ethics committee: Cantonal Ethics Committee Bern, Switzerland, ID 2016-01200; Medical Research Ethics Committee Utrecht, Netherlands, ID 15-522/D; Comité d’Ethique Hospitalo-Facultaire Saint-Luc-UCL: 2016/20JUL/347–Belgian registration No: B403201629175; Cork University Teaching Hospitals Clinical Ethics Committee, Cork, Republic of Ireland; ID ECM 4 (o) 07/02/17), and Swissmedic as the responsible regulatory authority.
: Written informed consent was obtained from the patients or their legal representatives before enrolment in the OPERAM trial.
: Authorship eligibility is based on the International Committee of Medical Journal Editors authorship criteria. The authors certify that they have participated in the conception and design (BS, CH, TE, EvP, DOM, AS, NR, IW, WK), acquisition and interpretation of data (BS, CH, JoH, IS, TE, EvP, IW, WK, NR, AS, DOM), drafting the article (BS, CH), and revising it critically for important intellectual content (all authors). All authors approved the final article.